MCL1, a member of the BCL2 family, is particularly associated with chemo-resistance and poor prognosis [7, 8] suggesting that therapeutic strategies targeting this protein may be of particular value in CLL. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.